BCLI logo

BCLI

Profile

Full Name

Brainstorm Cell Therapeutics Inc.

Ticker Symbol

BCLI

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

October 7, 2003

Indexes

Not included

Website

http://www.brainstorm-cell.com

Employees

27

Key Details

Price

$0.80(+2.56%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$2.31(+61.50% YoY)

PE ratio

-

Next earnings date

May 14, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.80
BCLI price is $0.80

30-Day Relative Volume

0.43
BCLI 30-day relative volume is 0.43

Price Performance

Price Most recent change

+2.56%
BCLI price was up +2.56% on Apr 16, 2025

Price YTD change

-64.76%
BCLI price is down -64.76% since January 1st

Price 1-year change

-90.12%
BCLI price is down -90.12% year-on-year

Price 3-year change

-98.31%
BCLI price is down -98.31% over the past 3 years

Price Range

Price All-time high

$776.25
BCLI price is currently -99.90% below its historical high of $776.25

Price 3-year low

$0.13
BCLI price is currently +515.38% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$4.91M
BCLI market capitalization is $4.91 million

Market cap 3-year change

-95.72%
BCLI market capitalization is down -95.72% over the past 3 years

Market cap All-time high

$559.69M
BCLI market capitalization is currently -99.12% below its historical high of $559.69 million

Market cap sector rank

13.08%
BCLI market capitalization is higher than 13.08% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+34.6%
BCLI shares outstanding is up +34.6% year-on-year

Shares Outstanding 3-Year Change

+152.5%
BCLI shares outstanding is up +152.5% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.51
BCLI beta is 0.51

200-day SMA

$2.69
BCLI price is currently -70.29% below its 200-day simple moving average

50-day SMA

$1.46
BCLI price is currently -45.27% below its 50-day simple moving average

RSI

22.46
BCLI 14-day relative strength index is 22.46

Volume

0.43
BCLI 30-day relative volume is 0.43

ATR

$0.12
BCLI average true range is $0.12

10-day Historical Volatility

121.89%
BCLI 10-day historical volatility is 121.89%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
BCLI annual revenue value is unknown

Revenue Analysts estimate

-
BCLI annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
BCLI annual revenue 1-year change is unknown

Revenue Sector rank

-
BCLI annual revenue is unknown

EPS

EPS

-$2.31
BCLI annual earnings per share is -$2.31

EPS Analysts estimate

-$2.21
BCLI annual earnings per share is currently +4.52% higher than the consensus analysts' forecast

EPS 1-year change

+61.5%
BCLI annual earnings per share is up +61.5% year-on-year

EPS Sector rank

36.12%
BCLI annual earnings per share is higher than 36.12% of companies in Healthcare sector

Profit

Gross profit

-
BCLI annual gross profit value is unknown

Gross margin

-
BCLI annual gross profit margin value is unknown

Operating profit

-$11.69M
BCLI annual operating income is -$11.69 million

Operating margin

-
BCLI annual operating profit margin value is unknown

Net income

-$11.62M
BCLI annual net profit is -$11.62 million

Net margin

-
BCLI annual net profit margin value is unknown

Expenses

Total expenses

$11.69M
BCLI annual total expenses is $11.69 million

Operating expenses

$11.69M
BCLI annual total operating expenses is $11.69 million

Cost of goods sold

-
BCLI annual cost of goods sold value is unknown

Selling, general & administrative expenses

$7.04M
BCLI annual SGA is $7.04 million

Depreciation and amortization

$240.00K
BCLI annual depreciation & amortization is $240.00 thousand

Interest expense

-
BCLI annual interest expense value is unknown

Income tax

-
BCLI annual income tax value is unknown

EBIT & EBITDA

EBIT

-$11.69M
BCLI annual earnings before interest & taxes is -$11.69 million

EBITDA

-$11.45M
BCLI annual EBITDA is -$11.45 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.83M
BCLI annual total assets is $1.83 million

Non current assets

$1.45M
BCLI annual long term assets is $1.45 million

Current assets

$385.00K
BCLI annual total current assets is $385.00 thousand

Cash and cash equivalents

$187.00K
BCLI annual cash & cash equivalents is $187.00 thousand

Accounts receivable

-
BCLI annual accounts receivable value is unknown

Inventory

-
BCLI annual inventory value is unknown

Liabilities

Total liabilities

$9.60M
BCLI annual total liabilities is $9.60 million

Long term liabilities

$618.00K
BCLI annual total long term liabilities is $618.00 thousand

Current liabilities

$8.98M
BCLI annual total current liabilities is $8.98 million

Accounts payable

$6.08M
BCLI annual accounts payable is $6.08 million

Debt

Total debt

$720.00K
BCLI annual total debt is $720.00 thousand

Total debt 1-year change

-43.53%
BCLI annual total debt is down -43.53% year-on-year

Long term debt

$171.00K
BCLI annual long term debt is $171.00 thousand

Short term debt

$549.00K
BCLI annual short term debt is $549.00 thousand

Equity & Capital

Shareholders equity

-$7.76M
BCLI annual stockholders equity is -$7.76 million

Book value

-$7.76M
BCLI annual book value is -$7.76 million

Retained earnings

-$226.64M
BCLI annual retained earnings is -$226.64 million

Working capital

-$8.59M
BCLI annual working capital is -$8.59 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$9.09M
BCLI annual cash flow from operations is -$9.09 million

Cash from operations 1-year change

+55.55%
BCLI annual cash flow from operations is up +55.55% year-on-year

Cash from investing

$12.00K
BCLI annual cash flow from investing activities is $12.00 thousand

Cash from investing 1-year change

-99.45%
BCLI annual cash flow from investing activities is down -99.45% year-on-year

Cash from financing

$7.97M
BCLI annual cash flow from financing activities is $7.97 million

Cash from financing 1-year change

-58.02%
BCLI annual cash flow from financing activities is down -58.02% year-on-year

CAPEX

CAPEX

-
BCLI annual capital expenditures value is unknown

CAPEX 1-year change

-
BCLI annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$9.09M
BCLI annual free cash flow is -$9.09 million

Free cash flow 1-year change

+55.59%
BCLI annual free cash flow is up +55.59% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
BCLI annual gross profit margin value is unknown

Operating margin

-
BCLI annual operating profit margin value is unknown

Net margin

-
BCLI annual net profit margin value is unknown

ROA & ROE

ROA

-634.44%
BCLI annual return on assets is -634.44%

ROE

149.70%
BCLI annual return on equity is 149.70%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
BCLI price to earnings ratio value is unknown

PE ratio Sector rank

-
BCLI price to earnings ratio is unknown

PB Ratio

PB ratio

-0.63
BCLI price to book ratio is -0.63

PB ratio Sector rank

9.97%
BCLI price to book ratio is higher than 9.97% of companies in Healthcare sector

PS Ratio

PS ratio

-
BCLI price to sales ratio value is unknown

PS ratio Sector rank

-
BCLI price to sales ratio is unknown

Enterprise value

Enterprise value

$5.45M
BCLI enterprise value is $5.45 million

Enterprise value Sector rank

19.98%
BCLI enterprise value is higher than 19.98% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.48
BCLI EV/EBITDA is -0.48

EV/EBITDA Sector rank

52%
BCLI EV/EBITDA is higher than 52% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

0.04
BCLI annual current ratio is 0.04

Quick ratio

-
BCLI annual quick ratio value is unknown

Leverage

Debt to equity

-0.09
BCLI annual debt to equity ratio is -0.09

Interest coverage ratio

-
BCLI annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
BCLI piotroski f-score value is unknown

Altman Z-Score

-
BCLI altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Jul 11, 24 Maxim Group
Buy
Sep 28, 23 Maxim Group
Hold
Mar 31, 23 Maxim Group
Buy
Feb 5, 21 Maxim Group
Buy
May 15, 18 HC Wainwright & Co.
Buy
May 15, 18 H.C. Wainwright
Buy
Aug 17, 17 Maxim Group
Buy

Institutional Ownership

Similar stocks

CMND logo
Clearmind Medicine (CMND)
CELZ logo
Creative Medical Technology Holdings (CELZ)
GTBP logo
GT Biopharma (GTBP)
GMDA logo
Gamida Cell (GMDA)
AEMD logo
Aethlon Medical (AEMD)
Azitra (AZTR)
Klotho Neurosciences (KLTO)
NSTG logo
NanoString Technologies (NSTG)
SPRB logo
Spruce Biosciences (SPRB)
  • What is the ticker symbol for Brainstorm Cell Therapeutics?
  • Does Brainstorm Cell Therapeutics pay dividends?
  • What sector is Brainstorm Cell Therapeutics in?
  • What industry is Brainstorm Cell Therapeutics in?
  • What country is Brainstorm Cell Therapeutics based in?
  • When did Brainstorm Cell Therapeutics go public?
  • Is Brainstorm Cell Therapeutics in the S&P 500?
  • Is Brainstorm Cell Therapeutics in the NASDAQ 100?
  • Is Brainstorm Cell Therapeutics in the Dow Jones?
  • When was Brainstorm Cell Therapeutics's last earnings report?
  • When does Brainstorm Cell Therapeutics report earnings?
  • Should I buy Brainstorm Cell Therapeutics stock now?

What is the ticker symbol for Brainstorm Cell Therapeutics?

The ticker symbol for Brainstorm Cell Therapeutics is NASDAQ:BCLI

Does Brainstorm Cell Therapeutics pay dividends?

No, Brainstorm Cell Therapeutics does not pay dividends

What sector is Brainstorm Cell Therapeutics in?

Brainstorm Cell Therapeutics is in the Healthcare sector

What industry is Brainstorm Cell Therapeutics in?

Brainstorm Cell Therapeutics is in the Biotechnology industry

What country is Brainstorm Cell Therapeutics based in?

Brainstorm Cell Therapeutics is headquartered in United States

When did Brainstorm Cell Therapeutics go public?

Brainstorm Cell Therapeutics's initial public offering (IPO) was on October 7, 2003

Is Brainstorm Cell Therapeutics in the S&P 500?

No, Brainstorm Cell Therapeutics is not included in the S&P 500 index

Is Brainstorm Cell Therapeutics in the NASDAQ 100?

No, Brainstorm Cell Therapeutics is not included in the NASDAQ 100 index

Is Brainstorm Cell Therapeutics in the Dow Jones?

No, Brainstorm Cell Therapeutics is not included in the Dow Jones index

When was Brainstorm Cell Therapeutics's last earnings report?

Brainstorm Cell Therapeutics's most recent earnings report was on Mar 31, 2025

When does Brainstorm Cell Therapeutics report earnings?

The next expected earnings date for Brainstorm Cell Therapeutics is May 14, 2025

Should I buy Brainstorm Cell Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page